Abiopharma

🔍 Temeng Kwaku (Executive)

Company: Core Laboratories Inc. /DE/ (CLB)

Report Date: 2026-04-01

Detailed Transactions and Holdings:

• Acquired 8,069 shares of Common Stock (Direct)
  Date: 2026-04-01 | Code: M | equity_swap_involved: false | shares_owned_after: 33,597.00 | transaction_form_type: 4
• Acquired 7,895 shares of Restricted Shares (Derivative)
  Date: 2026-04-01 | Code: A | equity_swap_involved: false | shares_owned_after: 7,895.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 8,069 shares of Restricted Shares (Derivative)
  Date: 2026-04-01 | Code: M | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F2, F2

Footnotes:

• F1: The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2027, subject to the terms of issuance. Such shares remain subject to a deferral election by the Reporting Person in accordance with Treasury Regulation 1.409A-2, and the vested portion thereof will be distributed as shares of common stock following the Reporting Person's separation of service from the Board.
• F2: The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2026.